WASHINGTON, DC: U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla in the Oval Office of the White House as he announces a deal with Pfizer to lower drug prices on September 30, ...
LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...
AstraZeneca PLC announced a deal with President Donald Trump that’s focused on lowering drug prices, in a move that would see the British drugmaker follow in the footsteps of Pfizer Inc. “Today, ...
Hosted on MSN
Trump’s AstraZeneca Deal Echoes Pfizer Pact. Big Pharma’s Political Headaches Are Easing.
The press conference that President Donald Trump hosted in the Oval Office with the CEO of drugmaker AstraZeneca on Friday played like a rerun of the late September Oval Office press conference with ...
Pfizer ended its six-month effort to buy AstraZeneca Monday following the London-based company's May 19 rejection of its last bid of 55 pounds a share in cash and stock. While British takeover law ...
Nov 9 (Reuters) - An AstraZeneca (AZN.L), opens new tab executive said he felt encouraged by "incredibly promising" COVID-19 vaccine trial data unveiled by Pfizer and its German partner BioNTech, ...
Shares of AstraZeneca (AZN +1.38%) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early ...
The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular franchises. For example, sales of Tagrisso, an EGFR inhibitor for the ...
LONDON, Oct 10 (Reuters) - Wall Street is looking to U.S. drugmaker Eli Lilly (LLY.N), opens new tab and Anglo-Swedish rival AstraZeneca (AZN.L), opens new tab as the potential next in line after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results